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We are investigating the structural thermodynamics and kinetics of cardiac
myosin in the presence of omecamtiv mecarbil (OM), a small molecule that
is currently in clinical trials for treating heart failure. AM has been shown to
increase thin-filament activated cardiac myosin ATPase activity, the apparent
rate constant for actin-activated phosphate release from cardiac myosin, and
contractility in the heart (Malik et al, Science 2011). HowOMmodulates theses
activities remains poorly understood. Based on a published Biophysical Society
Annual Meeting poster abstract (Liu et al. Biophys. J. 2013) and on published
studies (Malik et al, Science 2011), we hypothesized that OM stabilizes the pre-
powerstroke structural state in the presence of ATP analogs and increases the
observed rate constant for the actin-activated powerstroke during actin-
activated single ATP turnover. To test these predictions, we used a time-
resolved FRET biosensor of b-cardiac myosin, which detects the mole faction
of pre and post-powerstroke structural states of the myosin light-chain binding
domain, to determine the apparent equilibrium constant for the recovery-stroke
under saturating ADP, ADP.BeF, ADP.AlF and ADP.V nucleotide states in the
presence of saturating OM or DMSO. We varied the temperatures of these ex-
periments to determine whether OM changes the structural thermodynamics of
the pre-powerstroke state. In a second set of experiments, we directly measure
light-chain domain rotation during ATP binding to myosin and during actin
binding to myosin in the presence of ATP. Taken together, these results address
two of the key phenotypes that the drug exhibits in vitro, increased actin-
activated phosphate release, and increased thin-filament activated steady-
state ATPase cycling.
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Contractile dysfunction is a major problem in systolic heart failure and beta-
cardiac myosin provides the driving force for ventricular contraction in hu-
mans. The small molecule drug Omecamtiv Mecarbil (OM) specifically targets
cardiac myosin and is known to enhance cardiac muscle force generation,
while it is unclear how it impacts the structural properties of this motor. We
expressed and purified human b-cardiac myosin subfragment 1 (M2B-S1) by
generating recombinant adenovirus and infecting C2C12 embryonic muscle
cells. We demonstrate that the maximum actin-activated ATPase activity of
M2B-S1 is slowed 7-fold in the presence of 10 mM OM, while the actin con-
centration at which the ATPase activity is one-half maximal (KATPase) was
reduced dramatically (15-fold). The ATPase activity was less ionic strength
dependent in the presence of OM. We observed a concentration-dependent
inhibition of actin filament sliding velocity in the in vitro motility assay. We
generated another M2B-S1 construct that contained a tetracysteine site in
the upper 50 kDa domain (U50), which enables site-specific labeling of the
fluorescein biarscenical hairpin-binding dye (FlAsH). The conformation of
the U50 domain was examined by fluorescence resonance energy transfer
(FRET) as a function of temperature, using deacADP bound to the active
site (donor) and U50 FlAsH (acceptor). When comparing the low (10C)
and high (35C) temperature FRET, the presence of OM resulted in an increase
in the range distances, suggesting the U50 domain is more flexible in the pres-
ence of OM. Our results suggest that OM dramatically enhances the affinity for
actin which results in an increased duty ratio. The structural impact on the flex-
ibility of the U50 domain may enhance the coupling between the nucleotide
and actin binding regions and stabilize the actomyosin.ADP state with high
actin and ADP affinity.
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University, San Diego, CA, USA.Numerous myosin-based myopathies have been identified without a detailed
understanding of their molecular basis. To pursue mechanistic investigations,
we generated transgenic Drosophila expressing the R146N or R249Q myosin
mutations that cause hypertrophic cardiomyopathy in humans. Our studies
show severely compromised flight ability in homozygotes, with an age-
dependent worsening of muscle function and myofibrillar disarray in the indi-
rect flight muscle ultrastructure. The R146N mutation caused an increase in
basal Ca-ATPase andMg-ATPase activities, with a significant decrease in actin
motility. Semi-automated optical heartbeat analysis performed using high-
speed movies of semi-intact mutant heterozygous hearts indicated restrictive
cardiac physiology and diastolic dysfunction. Based upon molecular modeling,
we predict 1) the R146Nmutation alters ionic interaction of the N-terminal mo-
tor domain with E774 of the lever arm, resulting in failure of the lever arm to
cock prior to the power-stroke; and 2) the R249Q mutation disrupts electro-
static interaction with D262 of the central b-sheet domain, interrupting
communication between the ATP-binding and actin-binding sites. Thus, the
models imply that these conserved charge interactions are critical for myosin
function. To test these predictions, lines expressing R146E, E774R, R249D
and D262R mutations, as well as putative suppressor lines R146EþE774R
and R249DþD262R, will be studied using an integrative biochemical, biophys-
ical and physiological approach. Transgenic Drosophila expressing either
R146E or R249D myosin revealed more severe phenotypes relative to cardio-
myopathy mutations. Both homozygous mutants displayed flightless pheno-
types and highly compromised myofibrillar ultrastructure, with the R146E
mutants showing increased basal Ca-ATPase and Mg-ATPase activities, and
no actin motility. Heterozygotes present with severe restricted cardiac
physiology and diastolic dysfunction. Overall our studies indicate that the
Drosophila is a valuable tool to test significant myosin interactions during
health and disease. Supported by NIH R01GM32443 to SIB.
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Over 300 known mutations in human beta-cardiac myosin, the motor that
powers ventricular contraction, causes familial hypertrophic cardiomyopathy
(HCM) by altering the functional capacity of the cardiac sarcomere. The pre-
cise mechanism(s) by which these point mutations alter cardiac function and
lead to the clinically diverse HCM phenotypes is not well understood. The hu-
man heart is optimally designed to cyclically contract under varying loads and
it is likely that the mutations in beta-cardiac myosin affect the power output of
the heart by either altering force, velocity of contraction, or both, which ulti-
mately results in the observed clinical phenotypes.
Using ensemble in vitro motility experiments and single molecule force spec-
troscopy, we show that a truncated version (1-808 aa, containing human ELC)
of human beta-cardiac HCM-causing R403Q myosin mutant has ~15% lower
unitary force generated by a single head but has ~15% higher unloaded velocity
of contraction with pure actin. However, when studied with the six-component
regulatory thin filament (RTF) system (containing tropomyosin and the
troponin complex) the unloaded velocity of R403Q is unchanged. Loaded in vi-
tro motility measurements with both pure actin and RTFs indicate lower
ensemble force and therefore possibly lower power generated by this molecule.
Additional data suggests that R403Q myosin may have lower affinity for RTFs
than WT myosin, signifying a change in the duty ratio. Current efforts
exploring the effects of the R403Qmutation with a two-headed HMM construct
are underway.
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HCM is characterized by thickening of left ventricular wall and interventricular
septum, with abnormalities in contractile functions. It has been thought that
Tm’s flexible association with actin is important for its function. With in vitro
motility assays, we investigated a-Tmmutants V95A and D175N (based on hu-
man sequence), which are known to cause HCM. Reconstituted thin filaments
with rabbit skeletal actin and Tn were placed on HMM-coated glass surface. At
the room temperature (24C), we applied a microscopic heat pulse by focused
